Post-earnings recap
Reported
Thu, May 10, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a significant loss in EPS, which led to a 6.48% drop in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's financial health and future prospects. The management's defensive tone suggests they are aware of the challenges ahead.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.84 | N/A | -407.27% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial performance. They emphasized the importance of their clinical pipeline moving forward.
The company is focusing on its ongoing clinical trials.
Management acknowledged the challenges faced in the quarter.